NVS - Conatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promise
"Nothing can dim the light that shines from within" - Maya Angelou
Introduction
Conatus Pharmaceuticals (CNAT) is a small cap ($52M) clinical stage biopharma. Emricasan, a dual anti-apoptotic/anti-inflammatory oral irreversible pan-caspase inhibitor, is its lead investigative Phase 2b drug candidate currently being evaluated in 3 clinical trials as I alluded to in the summary.
On December 6, 2018, Conatus announced in a press release and subsequent conference call that top-line data readout from ENCORE-PH Phase 2b clinical trial in NASH Cirrhosis Portal Hypertension ((PH)) did not met its primary clinical outcome of significant